Skip Navigation

European Heart Journal 1993 14(Supplement A):38-44; doi:10.1093/eurheartj/14.suppl_A.38
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Parameshwar, J.
Right arrow Articles by Poole-Wilson, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parameshwar, J.
Right arrow Articles by Poole-Wilson, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

The role of calcium antagonists in the treatment of chronic heart failure

J. Parameshwar and P. A. Poole-Wilson

National Heart and Lung Institute Dovehottse Street, London SW3 6LY

Correspondence: Dr Jayan Parameshwar, Transplant Unit, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, U.K.

Calcium antagonists have been widely used for the treatment of angina and hypertension. Because of vasodilator and anti-ischaemic properties, calcium antagonists might be expected to bring benefit to patients with heart failure, particularly when the heart failure is due to coronary heart disease. Eight trials of calcium antagonists, fulfilling specific criteria, have been reviewed. The evidence at present does not support the use of calcium antagonists in established heart failure. Some benefit may accrue from the use of the newer calcium antagonists but further trials are awaited. Calcium antagonists appear to improve diastolic fraction in patients with coronary heart disease, no overt heart failure but a reduced ejection fraction.

Key Words: Heart failure • calcium antagonists • diastolic heart failure • ischaemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
R. S. Vasan, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, J. Sundstrom, J. M. Murabito, F. Sam, W. S. Colucci, and P. W. F. Wilson
Relations of Serum Aldosterone to Cardiac Structure: Gender-Related Differences in the Framingham Heart Study
Hypertension, May 1, 2004; 43(5): 957 - 962.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Karmazyn, Q. Liu, X. T. Gan, B. J. Brix, and L. Fliegel
Aldosterone Increases NHE-1 Expression and Induces NHE-1-Dependent Hypertrophy in Neonatal Rat Ventricular Myocytes
Hypertension, December 1, 2003; 42(6): 1171 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Bergdahl, S. Valdemarsson, X.-Y. Sun, T. Hedner, and L. Edvinsson
Enhanced Ca2+ -induced contractions and attenuated {alpha}-adrenoceptor responses in resistance arteries from rats with congestive heart failure
Eur J Heart Fail, January 1, 2001; 3(1): 7 - 13.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.